Medicina clinica · 2026
Three-year outcomes of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A real-world study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zamarrón de Lucas Ester, Crespo Catalán Clara, Romero Campos Belén, Sanz Sanjosé Belén, Longás Ouzzine María, Aponte Guevara Cindy Stephania, Álvarez-Sala Walther Rodolfo, Prados Sánchez María Concepción
Аннотация
INTRODUCTION: CFTR modulators have significantly changed the prognosis of cystic fibrosis (CF), although data on their long-term clinical and microbiological impact in adults in real-world practice remain limited.
OBJECTIVE: To analyze the clinical, functional, and microbiological outcomes at 36 months in adults with CF treated with elexacaftor/tezacaftor/ivacaftor (ETI).
METHODS: A longitudinal observational study was conducted in adults with CF. Lung function, number of exacerbations, weight, and sputum cultures were assessed at baseline and at 12, 24, and 36 months after initiation of ETI.
RESULTS: A total of 55 patients were included (43.6% female; mean age 32±13 years). FEV1 improved at 12 months and remained stable at 36 months. Exacerbations decreased, and weight increased progressively. The proportion of patients with potentially pathogenic microorganisms decreased from 93.1% at baseline to 36.2% at 36 months. Patients without microbiological isolation showed better lung function and fewer exacerbations.
CONCLUSIONS: In real-world clinical practice, ETI is associated with improvements in lung function, weight, and exacerbations, as well as a reduction in the isolation of potentially pathogenic microorganisms in sputum at 36 months.
OBJECTIVE: To analyze the clinical, functional, and microbiological outcomes at 36 months in adults with CF treated with elexacaftor/tezacaftor/ivacaftor (ETI).
METHODS: A longitudinal observational study was conducted in adults with CF. Lung function, number of exacerbations, weight, and sputum cultures were assessed at baseline and at 12, 24, and 36 months after initiation of ETI.
RESULTS: A total of 55 patients were included (43.6% female; mean age 32±13 years). FEV1 improved at 12 months and remained stable at 36 months. Exacerbations decreased, and weight increased progressively. The proportion of patients with potentially pathogenic microorganisms decreased from 93.1% at baseline to 36.2% at 36 months. Patients without microbiological isolation showed better lung function and fewer exacerbations.
CONCLUSIONS: In real-world clinical practice, ETI is associated with improvements in lung function, weight, and exacerbations, as well as a reduction in the isolation of potentially pathogenic microorganisms in sputum at 36 months.